Home » Stocks » Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc. (ARDS)

Stock Price: $6.50 USD 0.09 (1.40%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 58.00M
Revenue (ttm) n/a
Net Income (ttm) -28.12M
Shares Out 8.92M
EPS (ttm) -3.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $6.50
Previous Close $6.41
Change ($) 0.09
Change (%) 1.40%
Day's Open 6.41
Day's Range 6.23 - 6.95
Day's Volume 9,284
52-Week Range 3.80 - 12.40

More Stats

Market Cap 58.00M
Enterprise Value 41.68M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 8.92M
Float 5.20M
EPS (basic) -3.25
EPS (diluted) -3.25
FCF / Share -0.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 27,903
Short Ratio 3.01
Short % of Float 0.39%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 20.98
Revenue n/a
Operating Income -27.91M
Net Income -28.12M
Free Cash Flow -4.99M
Net Cash 16.32M
Net Cash / Share 1.83
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -77.08%
ROE -344.38%
ROIC 735.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(186.15% upside)
Current: 6.50
Target: 18.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-62.93%220.58%-62.1%-
Gross Profit1.022.760.860.34
Operating Income-29.09-24.12-19.74-7.88
Net Income-29.68-22.11-24.66-8.42
Shares Outstanding8.463.150.170.17
Earnings Per Share-3.51-7.45-148.20-50.62
Operating Cash Flow-8.16-24.27-17.56-6.09
Capital Expenditures-0.17-0.68-0.70-0.02
Free Cash Flow-8.33-24.95-18.26-6.11
Cash & Equivalents20.9024.2425.1022.29
Net Cash / Debt20.9024.2425.1022.29
Book Value3.6426.31-62.77-45.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aridis Pharmaceuticals Inc.
Country United States
Employees 25
CEO Vu L. Truong

Stock Information

Ticker Symbol ARDS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARDS
IPO Date August 10, 2018


Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.